Hikal Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Hikal Limited reported a net loss of Rs 487 million for FY2025-26, a sharp decline from profit of Rs 909 million in the previous year. Total revenue from operations fell to Rs 17,126 million from Rs 18,598 million, representing a 7.9% decline, impacted by USFDA warning letter for Jigani facility affecting Pharma segment sales. Exceptional items of Rs 851 million include impairment charge of Rs 471 million for assets at a repurposed plant and Rs 380 million from new labour code implementation (gratuity and compensation policy changes). Operating cash flow remained healthy at Rs 3,021 million. The Board recommended reduced dividend of 30% (Rs 0.60 per share) vs 70% in prior year. Auditors gave unmodified opinion with emphasis of matter on pending Supreme Court case regarding environmental compliance and Rs 174.5 million compensation claim.